Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

XOMA Royalty Corporation - Common Stock (NQ:XOMA)

30.67 -0.41 (-1.32%)

Streaming Delayed Price Updated: 2:08 PM EST, Dec 2, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	43,054
Open	31.45
Bid (Size)	30.60 (200)
Ask (Size)	30.97 (200)
Prev. Close	31.08
Today's Range	29.73 - 32.30
52wk Range	18.35 - 39.92
Shares Outstanding	11,782,723
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty

November 26, 2025

From Mural Oncology plc

Via GlobeNewswire

XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.

November 21, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

Performance

YTD	+18.0%	+18.0%
1 Month	-7.2%	-7.2%
3 Month	-11.8%	-11.8%
6 Month	+26.7%	+26.7%
1 Year	-5.4%	-5.4%

More News

XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

November 12, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting ↗

September 30, 2025

Via Stocktwits

Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty

October 24, 2025

From Mural Oncology plc

Via GlobeNewswire

LAVA Therapeutics Stock Drops After Amended Deal With XOMA Royalty ↗

October 17, 2025

Via Stocktwits

XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement

October 17, 2025

From XOMA Royalty Corporation; LAVA Therapeutics N.V.

Via GlobeNewswire

Mural Oncology To Be Acquired By Xoma Royalty ↗

August 20, 2025

Via Stocktwits

Turnstone Biologics: A $100 Dream Collides with a $0.34 Reality

October 17, 2025

Via MarketMinute

XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

October 02, 2025

From XOMA Royalty Corporation; LAVA Therapeutics

Via GlobeNewswire

XOMA Royalty Declares Quarterly Preferred Stock Dividends

September 22, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.

September 17, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference

September 03, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

August 20, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

HILLEVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX

August 19, 2025

From Kahn Swick & Foti, LLC

Via GlobeNewswire

XOMA Revenue Jumps 39% in Fiscal Q2 ↗

August 13, 2025

Via The Motley Fool

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

August 13, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

August 11, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)

August 04, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

August 04, 2025

From XOMA Royalty Corporation; LAVA Therapeutics N.V.

Via GlobeNewswire

HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right

August 04, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Carisma Therapeutics Inc. (Nasdaq - CARM), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC), Turnstone Biologics Corp. (Nasdaq - TSBX)

June 27, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Turnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment Slumps ↗

June 27, 2025

Via Stocktwits

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

June 27, 2025

From XOMA Royalty Corporation; Turnstone Biologics Corp.

Via GlobeNewswire

XOMA Royalty Declares Quarterly Preferred Stock Dividends

June 18, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

Frequently Asked Questions

Is XOMA Royalty Corporation - Common Stock publicly traded?

Yes, XOMA Royalty Corporation - Common Stock is publicly traded.

What exchange does XOMA Royalty Corporation - Common Stock trade on?

XOMA Royalty Corporation - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for XOMA Royalty Corporation - Common Stock?

The ticker symbol for XOMA Royalty Corporation - Common Stock is XOMA on the Nasdaq Stock Market

What is the current price of XOMA Royalty Corporation - Common Stock?

The current price of XOMA Royalty Corporation - Common Stock is 30.67

When was XOMA Royalty Corporation - Common Stock last traded?

The last trade of XOMA Royalty Corporation - Common Stock was at 12/02/25 02:08 PM ET

What is the market capitalization of XOMA Royalty Corporation - Common Stock?

The market capitalization of XOMA Royalty Corporation - Common Stock is 361.38M

How many shares of XOMA Royalty Corporation - Common Stock are outstanding?

XOMA Royalty Corporation - Common Stock has 361M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.